Cargando…
Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension
Right ventricular (RV) failure is the primary cause of death in pulmonary arterial hypertension (PAH). We hypothesized that heart‐relevant microRNAs, that is myomiRs (miR‐1, miR‐133a, miR‐208, miR‐499) and miR‐214, can have a role in the right ventricle in the development of PAH. To mimic PAH, male...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299706/ https://www.ncbi.nlm.nih.gov/pubmed/32395887 http://dx.doi.org/10.1111/jcmm.15352 |
_version_ | 1783547444210958336 |
---|---|
author | Kmecova, Zuzana Veteskova, Jana Lelkova‐Zirova, Katarina Bies Pivackova, Lenka Doka, Gabriel Malikova, Eva Paulis, Ludovit Krenek, Peter Klimas, Jan |
author_facet | Kmecova, Zuzana Veteskova, Jana Lelkova‐Zirova, Katarina Bies Pivackova, Lenka Doka, Gabriel Malikova, Eva Paulis, Ludovit Krenek, Peter Klimas, Jan |
author_sort | Kmecova, Zuzana |
collection | PubMed |
description | Right ventricular (RV) failure is the primary cause of death in pulmonary arterial hypertension (PAH). We hypothesized that heart‐relevant microRNAs, that is myomiRs (miR‐1, miR‐133a, miR‐208, miR‐499) and miR‐214, can have a role in the right ventricle in the development of PAH. To mimic PAH, male Wistar rats were injected with monocrotaline (MCT, 60 mg/kg, s.c.); control group received vehicle. MCT rats were divided into two groups, based on the clinical presentation: MCT group terminated 4 weeks after MCT administration and prematurely terminated group (ptMCT) displaying signs of terminal disease. Myocardial damage genes and candidate microRNAs expressions were determined by RT‐qPCR. Reduced blood oxygen saturation, breathing disturbances, RV enlargement as well as elevated levels of markers of myocardial damage confirmed PH in MCT animals and were more pronounced in ptMCT. MyomiRs (miR‐1/miR‐133a/miR‐208a/miR‐499) were decreased and the expression of miR‐214 was increased only in ptMCT group (P < 0.05). The myomiRs negatively correlated with Fulton index as a measure of RV hypertrophy in MCT group (P < 0.05), whereas miR‐214 showed a positive correlation (P < 0.05). We conclude that the expression of determined microRNAs mirrored the disease severity and targeting their pathways might represent potential future therapeutic approach in PAH. |
format | Online Article Text |
id | pubmed-7299706 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72997062020-06-18 Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension Kmecova, Zuzana Veteskova, Jana Lelkova‐Zirova, Katarina Bies Pivackova, Lenka Doka, Gabriel Malikova, Eva Paulis, Ludovit Krenek, Peter Klimas, Jan J Cell Mol Med Original Articles Right ventricular (RV) failure is the primary cause of death in pulmonary arterial hypertension (PAH). We hypothesized that heart‐relevant microRNAs, that is myomiRs (miR‐1, miR‐133a, miR‐208, miR‐499) and miR‐214, can have a role in the right ventricle in the development of PAH. To mimic PAH, male Wistar rats were injected with monocrotaline (MCT, 60 mg/kg, s.c.); control group received vehicle. MCT rats were divided into two groups, based on the clinical presentation: MCT group terminated 4 weeks after MCT administration and prematurely terminated group (ptMCT) displaying signs of terminal disease. Myocardial damage genes and candidate microRNAs expressions were determined by RT‐qPCR. Reduced blood oxygen saturation, breathing disturbances, RV enlargement as well as elevated levels of markers of myocardial damage confirmed PH in MCT animals and were more pronounced in ptMCT. MyomiRs (miR‐1/miR‐133a/miR‐208a/miR‐499) were decreased and the expression of miR‐214 was increased only in ptMCT group (P < 0.05). The myomiRs negatively correlated with Fulton index as a measure of RV hypertrophy in MCT group (P < 0.05), whereas miR‐214 showed a positive correlation (P < 0.05). We conclude that the expression of determined microRNAs mirrored the disease severity and targeting their pathways might represent potential future therapeutic approach in PAH. John Wiley and Sons Inc. 2020-05-12 2020-06 /pmc/articles/PMC7299706/ /pubmed/32395887 http://dx.doi.org/10.1111/jcmm.15352 Text en © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Kmecova, Zuzana Veteskova, Jana Lelkova‐Zirova, Katarina Bies Pivackova, Lenka Doka, Gabriel Malikova, Eva Paulis, Ludovit Krenek, Peter Klimas, Jan Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension |
title | Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension |
title_full | Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension |
title_fullStr | Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension |
title_full_unstemmed | Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension |
title_short | Disease severity–related alterations of cardiac microRNAs in experimental pulmonary hypertension |
title_sort | disease severity–related alterations of cardiac micrornas in experimental pulmonary hypertension |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299706/ https://www.ncbi.nlm.nih.gov/pubmed/32395887 http://dx.doi.org/10.1111/jcmm.15352 |
work_keys_str_mv | AT kmecovazuzana diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension AT veteskovajana diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension AT lelkovazirovakatarina diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension AT biespivackovalenka diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension AT dokagabriel diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension AT malikovaeva diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension AT paulisludovit diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension AT krenekpeter diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension AT klimasjan diseaseseverityrelatedalterationsofcardiacmicrornasinexperimentalpulmonaryhypertension |